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Abstract The type V transforming growth factor-L (TGF-L)
receptor (TLR-V) is hypothesized to be involved in cellular
growth inhibition by TGF-L1. Recently, TLR-V was found to
be identical to low density lipoprotein receptor-related protein-1
(LRP-1). Here we demonstrate that TGF-L1 inhibits growth of
wild-type CHO cells but not LRP-1-de¢cient mutant cells
(CHO-LRP-13 cells). Stable transfection of CHO-LRP-13
cells with LRP-1 cDNA restores the wild-type morphology
and the sensitivity to growth inhibition by TGF-L1. In addition,
overexpression of LRP-1 minireceptors exerts a dominant neg-
ative e¡ect and attenuates the growth inhibitory response to
TGF-L1 in wild-type CHO cells. These results suggest that
LRP-1/TLR-V is critical for TGF-L1-mediated growth inhibi-
tion in CHO cells.
0 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The type V transforming growth factor-L (TGF-L) receptor
(TLR-V) was identi¢ed as a high-molecular-weight receptor
which co-expresses with other TGF-L receptor types in most
cell types [1^3]. It was subsequently found to be identical to
the insulin-like growth factor-binding protein-3 (IGFBP-3)
receptor which mediates the IGF-independent growth inhibi-
tory response upon stimulation of IGFBP-3 in responsive cells
[4,5]. Many carcinoma cells produce little or no TLR-V and
do not respond to growth inhibition induced by IGFBP-3 or
TGF-L. Loss of TLR-V is hypothesized to contribute to the
malignant phenotype. Surprisingly, TLR-V was recently also
found to be identical to low density lipoprotein receptor-re-
lated protein-1 (LRP-1) [6]. This ¢nding was unexpected be-
cause LRP-1 has generally been recognized as an endocytic
receptor involved in plasma clearance and cellular degrada-
tion of ligands [7^10].
LRP-1 is synthesized as a 600-kDa type I membrane glyco-
protein. It can be cleaved into a 515-kDa heavy chain and an
85-kDa light chain upon proteolytic processing after biosyn-
thesis [7^11]. These two chains are held together by non-
covalent forces. Both the two-chain and intact molecules of
LRP-1 are present on the cell surface [6]. The light chain of
LRP-1 contains a transmembrane domain and a cytoplasmic
domain which includes endocytic motifs and the phosphory-
lation sites for cAMP-dependent protein kinase and the plat-
eled-derived growth factor-L-type receptor [12^15]. The heavy
chain of LRP-1 consists of several structural units: ligand-
binding complement-type cysteine-rich repeats, EGF-like cys-
teine-rich repeats and YWTD motifs. These repeats are ar-
ranged in four clusters containing two, eight, 10 and 11 re-
peats which are referred to as domains I, II, III and IV,
respectively. Domains II and IV are responsible for binding
most known LRP-1 ligands [7^11].
LRP-1 is identical to the activated K2-microglobulin (K2M*)
receptor [16]. K2M* has been shown to reduce N-methyl-D-
aspartic acid receptor-mediated Ca2þ in£ux in neurons and
stimulate a rise in cytoplasmic Ca2þ in 1-LN human prostate
cancer cells and murine macrophages [17^20]. Increasing evi-
dence indicates that LRP-1 is capable of mediating signals
other than Ca2þ in£ux [21]. The identi¢cation of TLR-V as
LRP-1 means that LRP-1 has a previously unreported growth
regulatory function [6]. This newly identi¢ed function of LRP-
1 may explain the embryonic lethal phenotype of the LRP-1
gene null mutation in animals [22]. Since LRP-1/TLR-V seems
to be quite signi¢cant in animal biology, we decided to inves-
tigate its role in the growth inhibitory response to TGF-L1 in
Chinese hamster ovary (CHO) cells. Wild-type CHO cells
(CHO-K1 cells) and mutant cells which are de¢cient in
LRP-1 (CHO-LRP-13 cells) [23] provide a model cell system
to test the role of LRP-1 in the growth inhibitory response to
TGF-L1. In this communication, we demonstrate that LRP-1/
TLR-V is required for growth inhibition induced by TGF-L1
in the CHO cell system.
2. Materials and methods
2.1. Materials
Na125I (17 Ci/mg) and [methyl-3H]thymidine (67 Ci/mmol) were
purchased from ICN Biochemical (Irvine, CA, USA). Dulbecco’s
modi¢ed Eagle’s medium (DMEM)/Ham’s F-12 medium, hygro-
mycin, G418, murine monoclonal antibody to HA peptide (YPYDVP-
DYA) and chloramine T were obtained from Sigma (St. Louis, MO,
USA). Precision protein standards and protein molecular weight
markers were obtained from Bio-Rad (Hercules, CA, USA) and
Promega (Madison, WI, USA). Anti-human LRP light chain serum
(carboxy-terminal 15-residue peptide) was prepared as described pre-
viously [6]. Rabbit anti-LRP-1 (whole molecule) serum was provided
by Dr. Dudley K. Strickland, Department of Vascular Biology, Amer-
ican Red Cross, Rockville, MD, USA. GST-RAP (a fusion protein of
glutathione S-transferase and receptor-associated protein) was ex-
pressed in Escherichia coli using pGEX-KG-RAP (6.4 kb) plasmid
and puri¢ed according to the procedure of Herz et al. [24]. pGEX-
KG-RAP, pcDNA3.1(-)neo and pcDNA3.1(-)neo-LRP-1 plasmid
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were provided by Dr. Joachim Herz, Department of Molecular Ge-
netics, Texas Southwestern Medical Center, Dallas, TX, USA.
pcDNA3.0 and lipofectamine 2000 were obtained from Invitrogen
(Carlsbad, CA, USA). Disuccinimidyl suberate was obtained from
Pierce (Rockford, IL, USA). Human TGF-L1 was obtained from
Austral Biologicals (Santa Clara, CA, USA). Human IGFBP-3 (ex-
pressed in E. coli ; MW V35 000) was obtained from Upstate (Char-
lottesville, VA, USA). CHO-K1 cells were obtained from American
Type Culture Collection (Rockville, MD, USA). CHO-LRP-13 cells
[23] were provided by Dr. Guejun Bu, Department of Pediatrics and
Cell Biology and Physiology, Washington University, St. Louis, MO,
USA. K2M* was prepared as described previously [25,26].
2.2. Preparation of cDNA constructs
The cDNA of LRP-1 was obtained by digestion of pcDNA3.1-
LRP-1 [6] with EcoRV. The LRP-1 cDNA fragment was then ligated
into the XhoI site of the pCXN vector after addition of phosphory-
lated XhoI linkers and XhoI digestion. LRP-1 minireceptor (mLRP)
cDNAs contained three parts: encoding signal peptide with an at-
tached HA tag, the ligand-binding minidomain (domain I, II, II or
IV) and the LRP-1 light chain. These mLRP cDNAs were prepared
according to the procedures published by Obermoeller-McCormick et
al. [27]. Brie£y, the relevant DNA sequences were synthesized by
polymerase chain reaction (PCR) using primers as described previ-
ously [27]. The PCR products were puri¢ed and ligated into the vector
pcDNA 3.0. These constructs were named pcDNA 3.0-mLRPI,
pcDNA 3.0-mLRPII, pcDNA 3.0-mLRPIII and pcDNA 3.0-
mLRPIV for constructs containing cDNAs of mLRPI, mLRPII,
mLRPIII, and mLRPIV, respectively.
2.3. Transfection
Cells were grown on 24-well dishes (2U105/well) in DMEM/Ham’s
F-12 medium containing 10% fetal calf serum. For LRP-1 cDNA
transfection, CHO-LRP-13 cells [23] were transfected with 0.8 Wg
pCXN-LRP-1+0.04 Wg pcDNA 3.1-Hygro or 0.8 Wg pCXN+0.04 Wg
pcDNA 3.1-Hygro (vectors) using lipofectamine 2000 [28]. Hygro-
mycin-resistant cells were selected with 600 Wg/ml of hygromycin
and 1000 Wg/ml of G418 in DMEM/Ham’s F-12 medium containing
10% fetal calf serum. CHO-LRP-13 cells already expressed the neo
gene [27]. G418 included in the selection medium was used to amplify
the LRP-1 cDNA insert in the pCXN vector in transfected cells [29].
The selected clones were named CHO-LRP-13/LRP-1 and CHO-
LRP-13/vector cells, respectively. Four to six clones were selected
for each cell type. For mLRP cDNA transfection, CHO-K1 and
CHO-LRP-13 cells were transfected with 0.8 Wg of pcDNA 3.1-
mLRPs or vector only using the same lipofectamine 2000 method.
The transfected cells were selected with 1000 Wg/ml of G418. The
selected clones were named CHO-K1/mLRPI, CHO-LRP-13/mLRPI,
CHO-K1/mLRPII, CHO-LRP-13/mLRPII, CHO-K1/mLRPIII,
CHO-LRP-13/mLRPIII, CHO-K1/mLRPIV and CHO-LRP-13/
mLRPIV cells, which expressed mLRPI, mLRPII, mLRPIII and
mLRPIV, respectively. CHO-K1/vector and CHO-LRP-13/vector
cells were CHO-K1 and CHO-LRP-13 cells stably transfected with
vector only, respectively. Four to six clones were selected for each cell
type. These cells were maintained in the same medium containing 400
Wg/ml of G418.
2.4. [125I]IGFBP-3 a⁄nity labeling
Cells were a⁄nity-labeled with [125I]IGFBP-3 according to pub-
lished procedures [4,5]. The [125I]IGFBP-3 a⁄nity-labeled TLR-V
was analyzed by 5% sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) and autoradiography.
2.5. Western blot analysis
Cells were lysed with 1% Triton X-100. The cell lysates were sub-
jected to Western blot analysis using murine monoclonal antibody to
HA, and rabbit antiserum to the light chain of LRP-1 or to the whole
molecule of LRP-1 followed by 5 or 10% SDS^PAGE. The antigen
band on the blot was visualized using the ECL system and quantitated
using Image Quant.
2.6. [125I]K2M* binding analysis
[125I]K2M* was prepared using methylamine-activated human K2M*
and the chloramine T method as described previously [25,26]. Cells
were incubated with 10 nM of [125I]K2M* in the presence or absence
of 15 Wg/ml of GST-RAP. The presence of GST-RAP was used to
estimate non-speci¢c binding of [125I]K2M*. After 2.5 h at 0‡C, the
binding was determined. Speci¢c binding was determined by subtract-
ing non-speci¢c binding from total binding.
2.7. [Methyl-3H]thymidine incorporation assay
Cells grown on 48-well clustered dishes (0.5U105/well) in DMEM/
Ham’s F-12 medium containing 0.1% fetal calf serum were treated
with increasing concentrations of TGF-L1 [6]. After incubation at
37‡C for 18 h, the cells were washed twice with 10% trichloroacetic
acid and once with 0.5 ml of ethanol:ether (2:1, v/v) and dissolved in
0.2 N NaOH for scintillation counting.
2.8. Cell growth assay
The cell growth assay was carried out as previously described [6].
Cells were treated with or without 100 pM of TGF-L1 in DMEM/
Ham’s F12 medium containing 1% fetal calf serum. Additional TGF-
L1 (100 pM) or solvent vehicle was added to the medium in the second
day of incubation. The cell number was counted 1 day later using a
hematocytometer.
2.9. Endocytosis
Endocytosis of cell surface-bound [125I]K2M* in CHO-K1/vector
and CHO-K1 cells stably expressing mLRPs was carried out as de-
scribed previously [27,30]. Cells grown on 35-mm Petri dishes were
incubated with 10 nM [125I]K2M* in the presence or absence of 15 Wg/
ml GST-RAP in DMEM/Ham’s F-12 medium (bicarbonate-free) con-
taining 0.1% bovine serum albumin. After 2 h at 0‡C, cells were
washed with cold bu¡er (50 mM HEPES, pH 7.4, 128 mM NaCl,
5 mM MgSO4 and 1.2 mM CaCl2). Endocytosis of cell surface-bound
[125I]K2M* was started by addition of 37‡C-prewarmed DMEM/
Ham’s F-12 medium. After various time periods at 37‡C, cells were
treated with 0.5 mg/ml of trypsin in phosphate-bu¡ered saline con-
taining 0.5 mM EDTA at 0‡C for 20 min. The trypsin-released and
cell-associated radioactivity were determined and represented cell sur-
face-bound and internalized [125I]K2M*, respectively.
3. Results
3.1. TGF-L1 inhibits growth of CHO-K1 cells but not
CHO-LRP-13 cells
CHO-LRP-13 cells were derived from CHO-K1 cells by
mutagenesis of the cells followed by selection with Pseudomo-
nas exotoxin A [23]. These cells did not express detectable
endogenous LRP-1. The absence of LRP-1/TLR-V in CHO-
LRP-13 cells was demonstrated by [125I]IGFBP-3 a⁄nity la-
beling (Fig. 1A), Western blot analysis using antiserum to the
light chain of LRP-1 (Fig. 1B) and [125I]K2M* binding anal-
ysis (Fig. 1C). CHO-LRP-13 cells express as many TGF-L
type I, type II and type III receptors (TLR-I, TLR-II and
TLR-III) as the wild-type cells (CHO-K1 cells) as determined
by [125I]TGF-L1 a⁄nity labeling (data not shown). In CHO-
K1 cells, TLR-V cannot be detected by [125I]TGF-L1 a⁄nity
labeling because [125I]TGF-L1 a⁄nity-labeled TLR-III (which
migrates as a broad high-molecular-weight band on SDS^
PAGE) hinders the detection of [125I]TGF-L1 a⁄nity-labeled
TLR-V on SDS^PAGE as observed in several cell types [2].
[125I]IGFBP-3 a⁄nity labeling was, therefore, used to detect
cell surface TLR-V [3,4]. The light chain of LRP-1, which
contains the transmembrane and cytoplasmic domains, is sta-
ble and appropriate to use as an indicator for the measure-
ment of LRP-1 expression. The recovery of the LRP-1 heavy
chain varies with experimental conditions because it associates
non-covalently with the light chain [6]. For this reason, anti-
serum to the light chain of LRP-1 was used to identify LRP-1
[6]. K2M* is a well-characterized ligand for LRP-1 which is
ideal for measurement of cell surface expression of LRP-1
[16]. At the steady state, s 95% of LRP-1 is present in the
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intracellular compartments [7^11]. As shown in Fig. 1A, the
[125I]IGFBP-3 a⁄nity-labeled TLR-V complex was detected in
CHO-K1 cells (lane 1) but not in CHO-LRP-13 cells (lane 2).
CHO-K1 cells expressed LRP-1 whereas CHO-LRP-13 cells
did not (Fig. 1B, lane 1 versus lane 2). CHO-K1 cells also
showed speci¢c binding of [125I]K2M* to LRP-1, whereas
CHO-LRP-13/vector cells did not (Fig. 1C).
In preliminary studies, we found that unlike epithelial cells,
CHO-K1 cells exhibited growth inhibition by TGF-L1 but not
by IGFBP-3. To compare the e¡ect of TGF-L1 on both DNA
synthesis and cell growth between CHO-K1 and CHO-LRP-
13 cells, cells were incubated with increasing concentrations of
TGF-L1 for DNA synthesis determination or with 100 pM
TGF-L1 for cell growth assay. After 18 h at 37‡C, DNA syn-
thesis was determined by measuring [methyl-3H]thymidine in-
corporation into cellular DNA. For the cell growth assay, cell
number was counted after a 3-day incubation with or without
TGF-L1. As shown in Fig. 2A,B, TGF-L1 at 20 pM and 100
pM inhibited DNA synthesis and cell growth of CHO-K1
cells byV30% andV60%, respectively. By contrast, it stimu-
lated DNA synthesis of CHO-LRP-13 cells though it did not
signi¢cantly a¡ect growth of these cells in the cell growth
assay. These results suggest that although TGF-L is a growth
inhibitor for CHO-K1 cells, it fails to inhibit growth in CHO-
LRP-13/vector cells.
3.2. Stable transfection of CHO-LRP-13 cells with LRP-1
cDNA restores the wild-type morphology and the growth
inhibitory response to TGF-L1
TLR-V has recently been shown to mediate the growth in-
hibitory response to TGF-L1 in concert with other TGF-L
receptors [3,6]. It is likely that the lack of the growth inhibi-
tory response to TGF-L1 in CHO-LRP-13 cells is due to the
absence of LRP-1 in these cells. To test this, CHO-LRP-13
cells were stably transfected with LRP cDNA in pCXN vector
containing the neo gene or vector only and selected with
G418. The presence of G418 in the selection medium selected
for expression and ampli¢cation of the neo-containing vector,
Fig. 1. [125I]IGFBP-3 a⁄nity labeling (A), Western blot analysis (B) and [125I]K2M* binding analysis (C) in CHO-K1, CHO-LRP-13/vector and
CHO-LRP-13/LRP-1 cells. A: CHO-K1 (lane 1), CHO-LRP-13/vector (lane 2) and CHO-LRP-13/LRP-1 (lane 3) cells were a⁄nity-labeled
with [125I]IGFBP-3 according to published procedures [4,5]. The [125I]IGFBP-3 a⁄nity-labeled TLR-V was analyzed by 5% SDS^PAGE and
autoradiography. The arrow indicates the location of the [125I]IGFBP-3^TLR-V complex. B: Cell lysates of CHO-K1 (lane 1), CHO-LRP-13/
vector (lane 2) and CHO-LRP-13/LRP-1 (lane 3) cells were subjected to Western blot analysis using antisera to the light chain of LRP-1 and
L-actin. The arrow indicates the locations of the light chain of LRP-1 and L-actin. The ratio of the LRP-1 light chain and L-actin levels in
CHO-K1 cells was taken as 1. This ratio in CHO-LRP-13/LRP-1 cells was estimated to be 0.6 U 0.2 (n=3). C: CHO-K1, CHO-LRP-13/LRP-1
and CHO-LRP-13/vector cells were incubated with 10 nM [125I]K2M* in the presence and absence of 15 Wg/ml RAP (for estimating non-speci¢c
binding) at 0‡C for 2.5 h. The speci¢c binding of [125I]K2M* was estimated by subtracting non-speci¢c binding from total binding.
Fig. 2. E¡ect of TGF-L1 on DNA synthesis (A) and cell growth (B) in CHO-K1, CHO-LRP-1/vector and CHO-LRP-13/LRP-1 cells. CHO-
K1, CHO-LRP-13/LRP-1 and CHO-LRP-13/vector cells were incubated with increasing concentrations of TGF-L1 as indicated for DNA syn-
thesis assays (A) or with TGF-L1 (0 and 100 pM) for cell growth assays (B). After 18 h at 37‡C, DNA synthesis was determined by measure-
ment of [methyl-3H]thymidine incorporation into cellular DNA. The [methyl-3H]thymidine incorporation in cells treated without TGF-L1 was
taken as 100%. For cell growth assays, cells were counted after 3 days in culture. Data from CHO-K1 and CHO-LRP-13/LRP-1 cells treated
with TGF-L1 were compared with data from these cells treated without TGF-L1 by Student’s t-test (*P6 0.001). Data are representative of
four similar experiments.
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pCXN and simultaneous ampli¢cation of the LRP-1 cDNA
insert in the pCXN vector which was integrated into the tar-
geted cell genome [29]. The selected representative clones were
named CHO-LRP-13/LRP-1 and CHO-LRP-13/vector, re-
spectively. As shown in Fig. 1, CHO-LRP-13/LRP-1 ex-
pressed LRP-1 at a level comparable to that in wild-type cells
(CHO-K1 cells) as determined by [125I]IGFBP-3 a⁄nity label-
ing (Fig. 1A, lane 3 versus lane 1), Western blot analysis (Fig.
1B, lane 3 versus lane 1) and [125I]K2M* binding analysis (Fig.
1C). CHO-LRP-13/vector cells did not produce measurable
LRP-1 in these three assays. CHO-LRP-13/LRP-1 cells exhib-
ited a round shape, similar to that seen in wild-type cells
(CHO-K1 cells) (Fig. 3). By contrast, like untransfected
CHO-LRP-13 cells, CHO-LRP-13/vector cells had spindle
shape morphology (Fig. 3).
We then determined the e¡ect of TGF-L1 on DNA syn-
thesis in CHO-LRP-13/LRP-1, CHO-LRP-13/vector and
CHO-K1 cells. As shown in Fig. 2A, TGF-L1 inhibited
DNA synthesis in CHO-LRP-13/LRP-1 and CHO-K1 cells.
This is in contrast to the TGF-L1-stimulated DNA synthesis
seen in CHO-LRP-13/vector cells. At 20 pM, TGF-L1 inhib-
ited DNA synthesis by V5% and V30% in CHO-LRP-13/
LRP-1 and CHO-K1 cells, respectively, whereas it stimulated
DNA synthesis by V50% in CHO-LRP-13/vector cells. The
growth inhibitory response to TGF-L1 in these CHO cells was
also determined by directly counting cell number after the
cells had been treated with TGF-L1 for 3 days. As shown in
Fig. 2B, TGF-L1 (100 pM) inhibited growth of CHO-K1 and
CHO-LRP-13/LRP-1 cells by V60 and V30%, respectively
but did not signi¢cantly a¡ect growth of CHO-LRP-13/vector
cells. The magnitude of the growth inhibitory response to
TGF-L1 as determined by measurement of DNA synthesis
and cell number in CHO-LRP-13/LRP-1 cells appeared to
be less than that in CHO-K1 cells. This partial rescue of
TGF-L1-mediated growth inhibition may be due to unidenti-
¢ed alterations in the growth inhibitory response-related cel-
lular events in CHO-LRP-13 cells. CHO-LRP-13 cells were
originally produced by mutagenesis and selection with Pseu-
domonas exotoxin A. These results suggest that stable trans-
fection of CHO-LRP-13 cells with LRP-1 cDNA restores the
wild-type phenotype and the sensitivity to growth inhibition
by TGF-L1.
3.3. Overexpression of mLRPs attenuates the growth inhibitory
response to TGF-L1 in CHO-K1 cells
We hypothesized that LRP-1 not only binds TGF-L1 but
also is involved in mediating signaling which leads to growth
inhibition induced by TGF-L1 (in concert with other TGF-L
receptor types). If this hypothesis is correct, mLRPs contain-
ing individual cell surface ligand-binding domains [27] might
have the potential to function as dominant negative mutants
when they are overexpressed in cells expressing endogenous
LRP-1. To test this hypothesis, CHO-K1 cells were stably
transfected with HA-tagged mLRPI, II, III and IV cDNAs
and vector only. The clones selected were named CHO-K1/
mLRPI, CHO-K1/mLRPII, CHO-K1/mLRPIII and CHO-
K1/mLRPIV, respectively. These cells expressed the products
of these cDNA constructs of mLRPs with molecular masses
of intact mLRPs (V120 kDa for mLRPI, V200 kDa for
mLRPII, 230 kDa for mLRPIII and V200 kDa for
mLRPIV) and of the ligand binding domain or the heavy
chain of mLRPs (V40 kDa for mLRPI, V120 kDa for
mLRPII, V150 kDa for mLRPIII and V120 kDa for
mLRPIV) (Fig. 4A, lanes 2 and 5^7) as described previously
[27]. These mLRPs all had the same light chain (85 kDa) as
endogenous LRP-1 did. The expression levels for all mLRPs
were estimated to be V2.5^3.5-fold higher than that of en-
dogenous LRP-1 as determined by Western blot analysis using
antiserum to the light chain of LRP-1 (Fig. 4B, lanes 2^5
versus lane 1). The expression levels of the heavy chain of
endogenous LRP-1 in these CHO-K1 cells stably expressing
mLRPs were comparable to that in CHO-K1/vector cells (Fig.
4B, lanes 2^5 versus lane 1). This suggests that overexpression
of mLRPs does not greatly a¡ect the expression of endoge-
nous LRP-1. Among these mLRPs, only mLRPII and
mLRPIV exhibited [125I]IGFBP-3 binding as determined by
[125I]IGFBP-3 a⁄nity labeling (Fig. 4C, lanes 2 and 3).
mLRPI and mLRPIII did not have detectable [125I]IGFBP-3
binding (data not shown). Overexpression of these mLRPs all
attenuated the growth inhibitory response (as determined by
measurement of DNA synthesis and cell number) to TGF-L1
in CHO-K1 cells (Fig. 5A,B). By contrast, CHO-K1 cells sta-
bly transfected with vector only responded as untransfected
CHO-K1 cells did (Fig. 5A, versus Fig. 2A). These mLRPs
Fig. 3. Microscopic morphology of CHO-K1, CHO-LRP-13/vector
and CHO-LRP-13/LRP-1 cells.
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did not have detectable ability to mediate growth inhibition
by TGF-L1. As shown in Fig. 5B, CHO-LRP-13 cells stably
transfected with mLRPIV cDNA (CHO-LRP-13/mLRPIV
cells) did not respond to TGF-L1-induced growth inhibition.
Similar results were also obtained in CHO-LRP-13 cells sta-
bly expressing mLRPI, II and III (data not shown). These
results suggest these mLRPs are capable of functioning as
dominant negative mutants in CHO-K1 cells.
Fig. 4. Western blot analyses of mLRPs (A) and of the light chain and the heavy chain of LRP-1 (B) and [125I]IGFBP-3 a⁄nity labeling (C) in
CHO-K-1 cells stably expressing mLRPs. A: Cell lysates from CHO-K1/vector cells and CHO-K1 cells stably expressing mLRPs (mLRPI,
mLRPII, mLRPIII and mLRPIV) were analyzed by Western blot analysis using murine monoclonal antibody to HA following 10% (lanes 1
and 2) or 5% (lanes 3^7) SDS^PAGE. The closed arrowhead indicates the locations of intact mLRPs (V120 kDa for mLRPI, V200 kDa for
mLRPII, V230 kDa for mLRPIII and V200 kDa for mLRPIV) (lanes 4^7). The open arrowhead indicates the locations of the mLRP light
chains (V40 kDa for mLRPI, V120 kDa for mLRPII, V150 kDa for mLRPIII and V120 kDa for mLRPIV) (lanes 2, 5, 6 and 7). The as-
terisk indicates the locations of non-speci¢c bands. The open circle indicates the locations of the degradation products of mLRPI and
mLRPIII, which were also reported previously [27]. B: The cell lysates from CHO-K1/vector and CHO-K1 cells stably expressing mLRPs were
subjected to Western blot analysis using antiserum to LRP-1. The arrowhead indicates the locations of the light chain and the heavy chain of
LRP-1. The relative amounts of the LRP-1 heavy chain (from endogenous LRP-1) and of the LRP-1 light chain (from endogenous LRP-
1+mLRPs) in these CHO-K1 cells stably expressing mLRPI were determined using Image Quant. The relative amounts of the light chain of
LRP-1 were estimated to be 1, V3.5, V3.5, V2.5 and V3.0 in CHO-K1/vector, CHO-K1/mLRPI, CHO-K1/mLRPII, CHO-K1/mLRPIII and
CHO-K1/mLRPIV cells, respectively. C: CHO-K1 /vector (lane 1), CHO-K1/mLRPII (lane 3) and CHO-K1/mLRPIV (lane 2) cells were incu-
bated with 6 nM [125I]IGFBP-3 for 25 h at 0‡C. [125I]IGFBP-3 a⁄nity labeling was then performed. The arrow indicates the location of the
[125I]IGFBP-3^LRP-1/TLR-V complex. The arrowhead indicates the location of either the [125I]IGFBP-3^mLRPII or the [125I]IGFBP-3^
mLRPIV complex (MW V150 000).
Fig. 5. E¡ect of TGF-L1 on DNA synthesis (A) and cell growth (B) in CHO-K1/vector and CHO-LRP-13 cells stably expressing mLRPs.
CHO-K1 cells stably expressing mLRPs and vector only (K1/mLRPI, K1/mLRPII, K1/mLRPIII, K1/mLRPIV and K1/vector) and CHO-LRP-
13 cells stably expressing mLRPIV (LRP-13/mLRPIV cells) were treated with increasing concentrations of TGF-L1 as indicated for DNA syn-
thesis assays (A) or with 100 pM of TGF-L1 for cell growth assay (B). After 18 h at 37‡C, [methyl-3H]thymidine incorporation into cellular
DNA was determined. The [methyl-3H]thymidine incorporation in cells treated without TGF-L1 was taken as 100%. In the cell growth assay,
the cell number was counted after a 3-day incubation. All data points from CHO-K1/mLRPI, CHO-K1/mLRPII, CHO-K1/mLRPIII and
CHO-K1/mLRPIV cells (A) were statistically signi¢cant when compared with those in CHO-K1/vector cells (Student’s t-test, P6 0.05^0.001).
Data of the cell growth assay (B) from CHO-K1/vector cells treated with TGF-L1 were compared with data from these cells treated without
TGF-L1 by Student’s t-test (*P6 0.05). Data are representative of three similar experiments.
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3.4. Overexpression of mLRPs does not signi¢cantly a¡ect the
endocytosis rate of endogenous LRP-1 and TGF-L1-
induced PAI-1 expression in CHO-K1 cells
The ¢nding that various mLRPs containing individual do-
mains all a¡ect the growth inhibitory response to TGF-L1 was
unexpected. Although the binding site(s) for TGF-L1 in the
LRP-1 molecule has not been identi¢ed, it is possible but
unlikely that all four mLRPs are capable of binding TGF-
L1 and competing with endogenous LRP-1 for binding
TGF-L1. Since LRP-1 is a known endocytic receptor, it would
also be important to see whether overexpression of mLRPs
alters the endocytic rate of cell surface endogenous LRP-1.
The endocytosis rate of cell surface endogenous LRP-1 in
these CHO-K1 cells stably expressing mLRPs was measured
using [125I]K2M* as ligand as described previously [27,30]. As
shown in Fig. 6A, CHO-K1/mLRPI, CHO-K1/mLRPII,
CHO-K1/mLRPIII and CHO-K1/mLRPIV cells exhibited
similar endocytosis rates of cell surface endogenous LRP-1
(t1=2V20^30 s) when compared with that of cell surface
LRP-1 in CHO-K1/vector cells (t1=2V20^30 s) [27,30].
To determine the e¡ect of mLRP overexpression on TLR-I/
TLR-II/Smad2/3/4 signaling, we examined TGF-L1-induced
PAI-1 expression in CHO-K1 cells stably expressing mLRPs.
TGF-L-induced PAI-1 expression is known to be mainly
mediated by the TLR-I/TLR-II/Smad2/3/4 signaling cascade,
but TLR-V is not required for this TGF-L activity [3]. CHO-
K1/vector, CHO-K1/mLRPI, CHO-K1/mLRPII, CHO-K1/
mLRPIII, CHO-K1/mLRPIV, CHO-LRP-13/vector and
CHO-LRP-13/LRP-1 cells were treated with 100 pM TGF-
L1 for 2 h. Northern blot analyses of PAI-1 and glyceralde-
hyde-3-phosphate dehydrogenase (G3PDH) in these cells were
performed. As shown in Fig. 6B, TGF-L1 induced expression
of PAI in all of these CHO cells expressing mLRPs (lanes
1^10), suggesting that TLR-I/TLR-II/Smad2/3/4 signaling is
functional in CHO-K1 cells stably expressing mLRPs. It is
also important to note that the TGF-L1-induced expression
of PAI-1 was greater in CHO-LRP-13/vector cells than in
other CHO cells, including CHO-K1/vector and CHO-LRP-
13/LRP-1 cells (lanes 13/14 versus lanes 1/2 or 11/12). This
suggests that LRP-1/TLR-V may play a negative regulatory
role in regulating TLR-I/TLR-II/Smad2/3/4 signaling.
4. Discussion
TGF-L is a potent growth inhibitor for many cell types [31^
33]. The growth inhibitory activity of TGF-L has been impli-
cated in many physiological and pathological processes.
Understanding the mechanism by which TGF-L inhibits cell
growth would be important to de¢ne the molecular basis of
these biological processes. Accumulating evidence indicates
that other signaling cascades, in addition to the classical
TLR-I/TLR-II/Smad2/3/4 cascade, are involved in mediating
the growth inhibitory response to TGF-L [34^40]. Recently,
LRP-1/TLR-V has been shown to be required, in concert with
other TGF-L receptor types, for mediating the growth inhib-
itory response to TGF-L1 in epithelial cells and carcinoma
cells [6]. There are several lines of evidence for this. (1) Re-
duced expression of LRP-1 by mutagenesis and selection with
Pseudomonas exotoxin A attenuates the growth inhibitory re-
sponse to TGF-L1 in mink lung epithelial cells [6]. (2) Carci-
noma cells expressing little or no TLR-V or LRP-1 do not
exhibit the growth inhibitory response to TGF-L1 [2,4,6,41,
42]. (3) Stable transfection with LRP-1 cDNA restores sensi-
tivity to TGF-L1-induced growth inhibition in a human lung
Fig. 6. Cell surface [125I]K2M* endocytosis (A) and TGF-L1-stimulated PAI-1 expression (B) in CHO-K1 cells stably expressing mLRPs. A:
CHO-K1 cells stably expressing vector, mLRPI, mLRPII, mLRPIII and mLRPIV were incubated with 10 nM [125I]K2M* in the presence or ab-
sence of GST-RAP (15 Wg/ml). After 2.5 h at 0‡C, the endocytosis of cell surface [125I]K2M* was carried out at 37‡C for di¡erent time periods
as indicated. Cell surface-associated and internalized [125I]K2M* were determined after trypsin digestion of cells at 0‡C. The trypsin-released
and cell-associated radioactivity represented cell surface-bound and internalized [125I]K2M*, respectively. The presence of GST-RAP was used
to determine non-speci¢c binding. Internalization of cell surface [125I]K2M* reached the maximum after a 2^3-min incubation at 37‡C, which
represented V80^90% of the speci¢c binding prior to incubation at 37‡C. The maximum was taken as 100% of internalization. B: CHO-K1
cells stably expressing vector only and mLRPs (K1/vector, K1/mLRPI, K1/mLRPII, and K1/mLRPIII, and K1/mLRPIV cells) and CHO-LRP-
13 cells stably expressing LRP-1 and vector only (LRP-13/LRP-1 and LRP-13/vector cells) were treated with or without TGF-L1 (100 pM).
After 2 h at 37‡C, Northern blot analysis of PAI-1 and G3PDH were performed. The intensities of the transcripts were determined by a Phos-
phoImager. The ratio of PAI-1/G3PDH was taken as 1-fold of PAI-1 expression in cells treated without TGF-L1. The TGF-L1-induced PAI-1
expression was estimated to be 1.4-, 1.4-, 1.4-, 1.2-, 1.4-, 1.3- and 3.5-fold in CHO-K1/vector, CHO-K1/mLRPI, CHO-K1/mLRPII, CHO-K1/
mLRPIII, CHO-K1/mLRPIV cells, CHO-LRP-13/LRP-1 and CHO-LRP-13/vector cells (lanes 1/2^13/14, respectively).
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carcinoma cell line (H1299 cells) [6]. Neither reduced expres-
sion of LRP-1 nor stable transfection with LRP-1 cDNA in
these cells alters the expression of TLR-I, TLR-II and TLR-III
in these cells. In addition, the TGF-L1-induced transcriptional
activation of PAI-1 is unaltered in these cells by the manipu-
lation of LRP-1.
Since TGF-L1 inhibits growth of many cell types, it would
to be important to de¢ne the role of LRP-1 in the growth
inhibitory response to TGF-L1 in various cell types. Currently,
there are two known cell systems available for de¢ning the
role of LRP-1 in TGF-L1-induced growth inhibition using
rescue approaches. These are mouse embryonic ¢broblasts
(MEF cells)/LRP-1-de¢cient mouse embryonic ¢broblasts
(PEA-13 cells) [22] and CHO-K1/CHO-LRP-13 cells [23].
We have attempted to perform rescue experiments by stably
transfecting PEA-13 cells with LRP-1 cDNA. However, we
have been unable to generate stable clones of transfected
PEA-13 cells which produce LRP-1 at a level comparable to
that in wild-type cells (MEF cells). There are at least two
reasons for this : (1) MEF cells are ¢broblasts that normally
express v 3-fold higher levels of LRP-1 than other cell types,
e.g. epithelial cells [6], and (2) the size of LRP-1 cDNA is
V15 kb and the LRP-1 transgene appears to be unstable in
transfected cells [27]. On the other hand, we demonstrate here
that CHO-LRP-13 cells stably transfected with LRP-1 cDNA
in pCXN vector are relatively stable. They express a level of
the LRP-1 transgene product comparable to that of LRP-1 in
wild-type CHO cells (CHO-K1 cells), and should be suitable
for de¢ning the role of LRP-1 in the growth inhibitory re-
sponse to TGF-L1. However, we are unable to fully restore
the growth inhibitory response to TGF-L in CHO-LRP-13
cells by stable transfection with LRP-1 cDNA to make
them comparable to their parent CHO-K1 cells. In CHO-
LRP-13/LRP-1 cells, TGF-L1 inhibits DNA synthesis and
cell growth by V5% and V30%, respectively. These are less
than those of TGF-L1-induced DNA synthesis and cell growth
inhibition (V30% andV60%, respectively) in wild-type CHO
cells (CHO-K1 cells). Possibly, the CHO-LRP-13 cells, which
were originally generated by mutagenesis and selection with
Pseudomonas exotoxin A, have alterations in other cellular
events in addition to the loss of LRP-1 expression. Although
the stable transfection of CHO-LRP-13 cells with LRP-1
cDNA only partially rescues the growth inhibitory response
to TGF-L1, it is clearly distinct from the mitogenic response to
TGF-L1 in the parent cells (CHO-LRP-13 cells).
mLRPs have been used to demonstrate the functions of
each domain in ligand binding and endocytosis [27,43]. We
used the procedures developed by them to generate mLRP
constructs for studying the e¡ects of overexpression of these
mLRPs on the growth inhibitory response to TGF-L1 in
CHO-K1 cells. Unexpectedly, all of these mLRPs were found
to be capable of attenuating the growth inhibitory response to
TGF-L1 in transfected CHO-K1 cells. The molecular mecha-
nisms by which these mLRPs attenuate the growth inhibitory
response to TGF-L1 are currently unknown. Since all of these
mLRPs have the same light chain, which includes the trans-
membrane and cytoplasmic domains, the light chains of these
mLRPs may mediate the dominant negative mutant function.
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